As the number of Covid-19 cases in India rises again, the Drugs Controller General of India awarded Bharat Biotech's Covaxin a restricted emergency use authorization for children aged 6 to 12 years on Tuesday. In December 2021, the panel approved Covaxin for emergency usage in children above the age of 12. Following the re-opening of the schools, there has been a greater emphasis on vaccination youngsters. According to reports, Bharat Biotech has fifteen days to produce the safety data, including data on adverse events. Meanwhile, Zydus Cadila's ZyCoV-D vaccine has been approved for restricted emergency use in children over the age of 12.
